Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study
Diabetes & Vascular Disease Research · 2026-05 · 23 (3)
DOI: 10.1177/14791641261465360 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes & Vascular Disease Research, online erschienen am 30.06.2026. Verfasst von Abdul Qadeer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA. Hauptthemen laut MEDLINE: Tirzepatide, Diabetes Mellitus, Type 2, Obesity, Glucagon-Like Peptides. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
With the increasing use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists for managing obesity and type 2 diabetes, understanding their real-world effectiveness and safety is essential. This TriNetX analysis directly compares clinical outcomes among patients treated with tirzepatide vs semaglutide.
Method
We utilized data from the TriNetX Research Network, identifying patients aged > 40 years or with obesity (“BMI ≥ 30 kg/m2”) and type 2 diabetes (HbA1c ≥ 6.5% or fasting glucose.≥ 125 mg/dL). Qualifying events were restricted to May 1, 2022, through November 21, 2024. We established two cohorts: one initiating tirzepatide and another semaglutide, ensuring each patient had at least three prescriptions and no prior exposure to the comparator drug or other GLP-1 receptor agonists. The index date was defined as the first co-occurrence of the obesity/diabetes criteria and the respective drug prescription. To ensure comparability, we performed 1:1 propensity matching, resulting in 47,804 patients in each cohort. Outcomes, including all-cause mortality, MACE, heart failure exacerbation, ischemic stroke/TIA, hospitalization/ED use, dementia, UTI, adverse Gastrointestinal (GI) effects, and changes in HbA1c, were assessed within a 1-year window after the index date.
Results
Our matched cohort had a mean age of 75 years, with 45% male patients and 74% identified as white. Patients treated with tirzepatide experienced a significantly lower incidence of MACE at “(“3.7% vs 4.1% (RR 0.918, 95% CI 0.862-0.978). All-cause mortality was also lower with tirzepatide (0.2% vs. 0.4%; Risk Ratio 0.436, 95% CI 0.338-0.562). The tirzapetide group achieved better glycemic control with a lower mean HbA1c (6.565% vs. 6.848%; p < 0.001) during the follow-up. There was no significant difference in heart failure exacerbation or UTI incidence. GI side effects were slightly less frequent in the tirzepatide cohort (9.8% vs. 10.2%; Risk Ratio 0.959, 95% CI 0.924-0.997), while hospitalization or emergency visits were comparable between the two groups.
Conclusion
In this propensity matched cohort of patients with obesity and type 2 diabetes, tirzepatide demonstrated improved cardiometabolic outcomes compared to semaglutide, including lower all-cause mortality and lower HbA1c. These findings support the cardiovascular safety and efficacy of tirzapetide and highlight the need for further studies to evaluate its effectiveness in broader clinical populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
- Department of Cardiovascular Medicine, The University of Texas Medical Branch, Galveston, TX, USA.
- Department of Medicine, Mobile Infirmary Medical Center, Mobile, AL, USA.
- Department of Internal Medicine, Trinity Health Oakland/Wayne State University, Pontiac, Michigan, USA.
- Department of Internal Medicine, Prime South GME Consortium Harlingen Medical Center, TX, USA.
ORCID-Profile: Abdul Qadeer, Ibrahim Mortada, Afaq Motiwala
Zitieren
APA
Qadeer, A., Khalid, M. B., Syed, R., Jain, S., Zakaria, F., Khan, M. H. A., Gohar, N., Shoukat, A., Mortada, I., Hamza, I., Motiwala, A., Raja, M. W., Blackwell, T., & Jneid, H. (2026). Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study. Diabetes & Vascular Disease Research, 23(3). https://doi.org/10.1177/14791641261465360
Vancouver
Qadeer A, Khalid MB, Syed R, Jain S, Zakaria F, Khan MHA, et al. Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study. Diabetes & Vascular Disease Research. 2026;23(3). doi:10.1177/14791641261465360
BibTeX
@article{Qadeer2026,
author = {Qadeer, Abdul and Khalid, Marwah Bintay and Syed, Ridwan and Jain, Samiksha and Zakaria, Faiza and Khan, Muhammad Huzaifa Ahmed and Gohar, Najam and Shoukat, Ashraf and Mortada, Ibrahim and Hamza, Izhan and Motiwala, Afaq and Raja, Muhammad Waheed and Blackwell, Thomas and Jneid, Hani},
title = {Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study},
journal = {Diabetes & Vascular Disease Research},
year = {2026},
volume = {23},
number = {3},
doi = {10.1177/14791641261465360}
}
EUVIMED